Syndopa CR 50 200 mg
|Generic For||Sinemet CR|
|Generic Name||Carbidopa Levodopa|
|Manufacturer||Wyeth Pharmaceuticals, India|
|Pack Size||Qty||Price Per Pill or Unit||Price||Cart|
|30 Tablet/s||US$ 0.47||US$ 14.00|
|60 Tablet/s||US$ 0.38||US$ 23.0018%US$ 28.00|
|90 Tablet/s||US$ 0.34||US$ 30.5027%US$ 42.00|
Syndopa CR 50 200 mg is a sustained-release combination of Carbidopa and Levodopa for treating Parkinson’s disease and syndrome. Parkinson’s is a chronic disease defined as slow and unsteady movement, tremors, and muscular stiffness. If left untreated, this syndrome can cause difficulty performing normal daily activities. It is supplied as a tablet for oral administration. The tablets are formulated to slowly release two active ingredients: Carbidopa and Levodopa.
It is believed that Parkinson’s is caused due to lack of dopamine, a chemical produced naturally by certain brain cells. This chemical plays a crucial role in receiving messages in certain regions of the brain that control muscle movement. Problem with body movements develops when too little dopamine is produced. Levodopa replaces dopamine in the brain, while carbidopa ensures that an adequate amount of Levodopa gets into the brain where it is required. In many patients, this causes a significant reduction in Parkinson’s disease symptoms.
Hypersensitive patients to this medicine or its ingredients should not take Syndopa. Syndopa CR should not be administered to patients with clinical evidence of heart, pulmonary (including bronchial asthma), renal disease, or narrow-angle glaucoma. As with Levodopa, Syndopa CR should not be given when the administration of an amine is contraindicated (for example, isoproterenol, epinephrine, or norepinephrine). Because Levodopa may activate a malignant melanoma, Syndopa controlled release tablets should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
The most frequent side effects of the medicine include abnormal movements, nausea, confusion, hallucinations, dizziness, and dry mouth. Other possible side effects include sleepiness, abnormal dreams or difficulty sleeping, depression, flushing, hair loss, sweat, weakness, loss of appetite, fainting, discolouration of urine, saliva, and melanoma.
Syndopa CR 50 200 mg contains carbidopa and Levodopa in a 1:4 ratio of 50-200 tablets. The daily dosage of the medicine must be determined by careful titration by your doctor. Patients should be monitored closely during the dosage adjustment period, particularly concerning the appearance or worsening of nausea or abnormal involuntary movements. Although this medicine can have an effect after one day, it may take up to seven days to work. Do not change the times you take your controlled-release tablets or any other medicines for Parkinson’s disease without first talking to your doctor. You should not take medicine at intervals less than four hours apart.
Try to avoid taking this medicine with heavy meals. If you have not had Levodopa, the usual starting dose is one tablet twice daily. In this case, you will be advised to stop taking your medicine for Parkinson’s disease for eight hours before you start taking Syndopa tablets. The medicine is not suitable for children under the age of 18 years. Do not stop taking this medicine or change your dose without speaking to your doctor first. You may develop a high temperature, stiff muscles, and mental changes on treatment discontinuation.